Investors / United States / Astellas Venture Management
Astellas Venture Management
Corporate VC · South San Francisco, CA, United States · North America
Astellas Venture Management is the wholly-owned venture capital organization within Astellas. It provides equity investments to private, early-stage biotechnology companies developing therapeutic programs and platform technologies.
Invests inHealthcare & Biotech
In its own wordsbiotechtherapeuticsdrug discoveryplatform technologiespreclinicallife sciences
Your fit with Astellas Venture Management
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsAstellas Venture Management lists 24 checked portfolio companies on its own site and is named in 3 funding rounds, 1 of them as lead. Its most frequent entry is Series B, 67% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 50% of its companies are based in United States. It invests most often alongside JIC Venture Growth Investments, Kyoto University Innovation Capital and Sofinnova Partners.
Counts come from funding rounds that name Astellas Venture Management, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Astellas Venture Management's whole history. Rounds on record name 3 companies; its own site lists 24. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 33% |
| Series B | 67% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 0 | 0 |
| '26 | 3 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 59th | 24 companies |
| Recent activity | 76th | 3 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 73th | 8% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 58th | 3 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| JIC Venture Growth Investments | 3 |
| Kyoto University Innovation Capital | 3 |
| Sofinnova Partners | 3 |
| Ajinomoto Group Ventures | 2 |
| Canaan | 2 |
| DCVC | 2 |
| Lightstone Ventures | 2 |
| OSAKA University Venture Capital | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers24100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with JIC Venture Growth Investments
Compare Astellas Venture Management head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Astellas Venture Management| Date | Company | Stage |
|---|---|---|
| 20 Jun 2026 | Series A Led | |
| 15 Apr 2026 | Series B |
Round details for Astellas Venture Management
Amounts, full round histories and every co-investor in Astellas Venture Management's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
24 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Avilar Therapeutics is developing novel degraders of extracellular proteins as future standard of care medicines for the treatment of multiple serious diseases. | Healthcare & Biotech | Portfolio page | ||
| Bicycle Therapeutics is developing precision-guided therapeutics to target solid tumor cancers and other therapeutic applications | Healthcare & Biotech | Portfolio page | ||
| Casma Therapeutics is developing novel cellular degradation approaches based on the autophagy pathway to initiate new target areas for drug discovery and development | Healthcare & Biotech | Portfolio page | ||
| Catamaran Bio engineers NK cell therapies to provide treatments for solid tumors and other cancers. | Healthcare & Biotech | Portfolio page | ||
| The company is building a future where biology is no longer destiny, but design | Healthcare & Biotech | Portfolio page | ||
| Crescendo Biologics develops novel T cell enhancing therapeutics in immuno-oncology | Healthcare & Biotech | Portfolio page | ||
| The company develops cancer therapeutics | Healthcare & Biotech | Portfolio page | ||
| The company is a clinical stage biopharmaceutical company. | Healthcare & Biotech | Portfolio page | ||
| F2G develops therapeutics for rare fungal infections | Healthcare & Biotech | Portfolio page | ||
| Heartseed Inc. develops and delivers cardiac regenerative medicine to treat severe heart failure. | Healthcare & Biotech | Portfolio page | ||
| Mogrify develops a novel class of in vivo reprogramming therapies to transform the lives of patients with high unmet clinical needs. | Healthcare & Biotech | Portfolio page | ||
| NeoPhore develops a therapeutic approach that blocks DNA Mismatch Repair to make tumors sensitive to immunotherapy. | Healthcare & Biotech | Portfolio page | ||
| PhoreMost is a biotechnology company dedicated to turning scientific breakthroughs into life-changing cancer therapies. | Healthcare & Biotech | Portfolio page | ||
| Restore Vision develops a visual restoration gene therapy | Healthcare & Biotech | Apr 2026Series B | Page + round | |
| Shinobi Therapeutics engineers immune evasive and armored iPSCs to unlock the full potential of cell therapies. | Healthcare & Biotech | Portfolio page | ||
| Sidewinder Therapeutics is pioneering the next generation of bispecific antibody-drug conjugates to treat cancers. | Healthcare & Biotech | Portfolio page | ||
| Solu Therapeutics is pioneering a new therapeutic modality to transform patient lives by developing a new type of antibody therapeutic | Healthcare & Biotech | Portfolio page | ||
| Syntax Bio programs stem cells toward various cell types, including pancreatic beta cells, using its proprietary Cellgorithm technology. | Healthcare & Biotech | Jun 2026Series A | Page + round | |
| Tizona Therapeutics is developing first-in-class immunotherapies for cancer treatment | Healthcare & Biotech | Portfolio page | ||
| The company develops and researches regenerative treatments for teeth, including a treatment for congenital tooth loss. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- astellasventure.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 8 Apr 2026
- Companies checked
- 24
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Astellas Venture Management's profile as data
Pull Astellas Venture Management's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/astellasventure.com
# also
GET /v1/firms/astellasventure.com/portfolio
GET /v1/firms/astellasventure.com/coinvestors
GET /v1/firms/astellasventure.com/news